Evidence map›Paper›PMID 24586561›Full record

ArticlePloS one2014

Deletion of PREPl causes growth impairment and hypotonia in mice.

Anna Mari Lone, Mathias Leidl, Amanda K McFedries, James W Horner, John Creemers, Alan Saghatelian

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Anna Mari LoneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America.
Mathias LeidlDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America.
Amanda K McFedriesDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America.
James W HornerBelfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America ; Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
John CreemersLaboratory for Biochemical Neuroendocrinology, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Alan SaghatelianDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts, United States of America.
Harvard University · USKU Leuven · BE

Funding

Training in Molecular, Cellular, and Chemical BiologyT32GM007598 · NIGMS · HARVARD UNIVERSITY · PI DULAC, CATHERINE · 1985 to 2019
$16.2M
Discovery metabolite profiling of the prolyl peptidasesDP2OD002374 · OD · HARVARD UNIVERSITY · PI SAGHATELIAN, ALAN · 2007 to 2009
$2.6M
NIGMS NIH HHS GM007598NIGMS NIH HHS T32 GM007598NIH HHS 1DP2OD002374NIH HHS DP2 OD002374
6 · The paper itself

Abstract

Genetic studies of rare diseases can identify genes of unknown function that strongly impact human physiology. Prolyl endopeptidase-like (PREPL) is an uncharacterized member of the prolyl peptidase family that was discovered because of its deletion in humans with hypotonia-cystinuria syndrome (HCS). HCS is characterized by a number of physiological changes including diminished growth and neonatal hypotonia or low muscle tone. HCS patients have deletions in other genes as well, making it difficult to tease apart the specific role of PREPL. Here, we develop a PREPL null (PREPL(-/-)) mouse model to address the physiological role of this enzyme. Deletion of exon 11 from the Prepl gene, which encodes key catalytic amino acids, leads to a loss of PREPL protein as well as lower Prepl mRNA levels. PREPL(-/-) mice have a pronounced growth phenotype, being significantly shorter and lighter than their wild type (PREPL(+/+)) counterparts. A righting assay revealed that PREPL(-/-) pups took significantly longer than PREPL(+/+) pups to right themselves when placed on their backs. This deficit indicates that PREPL(-/-) mice suffer from neonatal hypotonia. According to these results, PREPL regulates growth and neonatal hypotonia in mice, which supports the idea that PREPL causes diminished growth and neonatal hypotonia in humans with HCS. These animals provide a valuable asset in deciphering the underlying biochemical, cellular and physiological pathways that link PREPL to HCS, and this may eventually lead to new insights in the treatment of this disease.

Indexed as

AnimalsChromosome DeletionChromosomes, Human, Pair 21Craniofacial AbnormalitiesCystinuriaExonsIntellectual DisabilityMiceMice, Inbred C57BLMice, Mutant StrainsMitochondrial DiseasesMuscle HypotoniaProlyl OligopeptidasesSerine EndopeptidasesPREPL protein, humanProlyl OligopeptidasesSerine Endopeptidases

Identifiers

PMID24586561
PMCPMC3938459
OpenAlexW2088464933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.